Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Terminated 14Recruiting 9Completed 8Unknown 5Active not recruiting 5Withdrawn 3Not yet recruiting 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 24Lymphoid 19Myeloid 8Gastrointestinal 7Plasma cell 5Dermatologic 4Gynecologic 3Genitourinary 3Breast 3Thoracic 2Sarcoma 2Head & Neck 2Other solid neoplasm 1Classical hematology 1CNS 1

Conditions

Uterine Cervical Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Metastatic Bladder Urothelial Carcinoma 1Melanoma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 19Docetaxel 16Magnetic Resonance Spectroscopy 14Prednisone 13Radiotherapy 11bicalutamide 10Leuprolide 10Abiraterone Acetate 9Radiosurgery 8Cyclophosphamide 8Biopsy 8avelumab 7atezolizumab 6Specimen Handling 6Interleukin-2 6Gemcitabine 6Bevacizumab 6Androgen Antagonists 6tremelimumab 5gallium 68 PSMA-11 5apalutamide 5acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 5Surveys and Questionnaires 5Sunitinib 5Paclitaxel 5Metformin 5Injections 5Goserelin 5Cisplatin 5ALT-803 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × fludarabine × Genitourinary × Clear all
NCT06626256 2025-12-24

STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma

City of Hope Medical Center

Phase 1 Withdrawn
DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT06094842 2025-04-01

Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer

Fred Hutchinson Cancer Center

Phase 1 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT03935347 2020-01-02

Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy

Roswell Park Cancer Institute

Phase 2 Withdrawn
Genitourinary

Metastatic Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡